产品
编 号：F490023
分子式：C17H15F2N3O3S
分子量：379.38
分子式：C17H15F2N3O3S
分子量：379.38
产品类型
规格
价格
是否有货
结构图
CAS No: 871313-59-6
产品详情
生物活性：
JNJ-27141491 is a selective, noncompetitive and orally active functional antagonist of human CCR2.
体内研究：
JNJ-27141491 (5-40 mg/kg; oral; once or twice daily) 抑制单核细胞和中性粒细胞招募到转基因 hCCR2 敲入小鼠的肺泡空气空间。JNJ-27141491 (20 mg/kg; oral; daily for 16 days) 在转基因 CCR2 小鼠中延迟实验性自身免疫性脑脊髓炎 (EAE)。Animal Model:Transgenic mCCR2 knockout/hCCR2 knockin C57BL/6 mice
Dosage:5, 10, 20, or 40 mg/kg
Administration:Oral, once or twice daily
Result:Once-daily oral treatment with 40, 20, 10, or 5 mg/kg inhibited the monocyte influx with 77, 57, 49, and 27%, respectively, compared with vehicle treatment, whereas this value was 74 and 22% after twice-daily oral treatment with 20 or 5 mg/kg. The neutrophil influx was also reduced; neutrophil numbers were decreased, with 56, 45, 20, and 8% after 40, 20, 10, or 5 mg/kg q.d. treatments and with 45 and 20% after 20 and 5 mg/kg b.i.d. treatments.
体外研究：
JNJ-27141491 抑制 MCP-1 诱导的 [35S]GTPγS 与 hCCR2-CHO 细胞膜的结合 (IC50=38±9 nM)，并减少 MCP-1 诱导的 Ca2+ 动员，在 hCCR2-CHO 细胞的 IC50 为 13±1 nM，在 THP-1 细胞的 IC50 为 13±2 nM 和在人血单核细胞的 IC50 为 43±4 nM。JNJ-27141491 也抑制人 PBMC 对 MCP-1 的趋化作用，其 IC50 值为 97±16 nM。JNJ-27141491 与 MCP-1 和 hCCR2 的结合竞争，并作为 CCR2 受体的非竞争性拮抗剂。
JNJ-27141491 is a selective, noncompetitive and orally active functional antagonist of human CCR2.
体内研究：
JNJ-27141491 (5-40 mg/kg; oral; once or twice daily) 抑制单核细胞和中性粒细胞招募到转基因 hCCR2 敲入小鼠的肺泡空气空间。JNJ-27141491 (20 mg/kg; oral; daily for 16 days) 在转基因 CCR2 小鼠中延迟实验性自身免疫性脑脊髓炎 (EAE)。Animal Model:Transgenic mCCR2 knockout/hCCR2 knockin C57BL/6 mice
Dosage:5, 10, 20, or 40 mg/kg
Administration:Oral, once or twice daily
Result:Once-daily oral treatment with 40, 20, 10, or 5 mg/kg inhibited the monocyte influx with 77, 57, 49, and 27%, respectively, compared with vehicle treatment, whereas this value was 74 and 22% after twice-daily oral treatment with 20 or 5 mg/kg. The neutrophil influx was also reduced; neutrophil numbers were decreased, with 56, 45, 20, and 8% after 40, 20, 10, or 5 mg/kg q.d. treatments and with 45 and 20% after 20 and 5 mg/kg b.i.d. treatments.
体外研究：
JNJ-27141491 抑制 MCP-1 诱导的 [35S]GTPγS 与 hCCR2-CHO 细胞膜的结合 (IC50=38±9 nM)，并减少 MCP-1 诱导的 Ca2+ 动员，在 hCCR2-CHO 细胞的 IC50 为 13±1 nM，在 THP-1 细胞的 IC50 为 13±2 nM 和在人血单核细胞的 IC50 为 43±4 nM。JNJ-27141491 也抑制人 PBMC 对 MCP-1 的趋化作用，其 IC50 值为 97±16 nM。JNJ-27141491 与 MCP-1 和 hCCR2 的结合竞争，并作为 CCR2 受体的非竞争性拮抗剂。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备